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Abstract: It is estimated that underlying infections and inflammatory responses are linked 
to 15–20% of all deaths from cancer worldwide. Inflammation is a physiologic process in 
response to tissue damage resulting from microbial pathogen infection, chemical irritation, 
and/or wounding. Tissues injured throughout the recruitment of inflammatory cells such as 
macrophages and neutrophils, generate a great amount of growth factors, cytokines, and 
reactive oxygen and nitrogen species that may cause DNA damage that in turn predisposes 
to the transformation from chronic inflammation to neoplasia. Cyclooxygenase (COX), 
playing a key role in cell homeostasis, angiogenesis and tumourigenesis, may represent the 
link between inflammation and cancer. Currently COX is becoming a pharmacological 
target for cancer prevention and treatment. 
Keywords: cyclooxygenase-2; non-steroidal anti-inflammatory drugs; esophageal cancer; 
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1. Introduction 
It was in 1863 that Rudolf Virchow indicated the link between cancer and inflammation on the 
basis of observations that tumours often arose at sites of chronic inflammation and that inflammatory 
cells were present in samples from tumours [1]. 
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With time, many epidemiologic evidences have supported Virchow’s hypothesis showing that 
chronic inflammatory diseases are frequently associated with increased risk of cancers [1–3]. Currently 
it is estimated that underlying infections and inflammatory responses are linked to 15–20% of all 
deaths from cancer worldwide [4]. For instance, the risk of colorectal cancer (CRC) was 10-fold 
greater if linked with an inflammatory bowel disease, such as ulcerative colitis and Crohn’s disease 
[5,6]. The risk of esophageal, gastric and pancreatic cancer may be increased by inflammatory 
diseases, such as esophagitis with Barrett’s metaplasia, chronic atrophic gastritis with intestinal 
metaplasia and chronic pancreatitis respectively [7,8]. Furthermore, the cancer risk appears to be 
positively associated with the severity and duration of inflammatory diseases [9]. 
But the question now is how does chronic inflammation develop into tumours and which are the 
driving mediators in this process. Inflammation is a physiologic process in response to tissue damage 
resulting from microbial pathogen infection, chemical irritation, and/or wounding [2]. Tissues injured 
throughout the recruitment of inflammatory cells such as macrophages and neutrophils, generate a great 
amount of growth factors, cytokines, and reactive oxygen and nitrogen species that may cause DNA 
damage [3,10]. If the inflammatory process is activated persistently it may lead to continuous tissue 
damage and an altered microenvironment that in turn sustains cell proliferation and predisposes to the 
transformation from chronic inflammation to neoplasia [1]. 
The chronic inflammation microenvironment is predominated by macrophages [10]. Macrophages 
generate a great amount of inflammatory mediators which react with DNA and cause mutations in 
proliferating epithelial and stroma cells [11,12]. Macrophages and T lymphocytes may release tumour 
necrosis factor-α (TNF-α) and macrophage migration inhibitory factor to exacerbate DNA damage [13]. 
Macrophages, neutrophils, eosinophils, dendritic cells, mast cells, and lymphocytes are also found to 
be key components in the epithelial-originated tumours [14]. Indeed, inflammatory cells act as tumour 
promoters in inflammation associated cancers. Tumour-associated macrophages (TAM) are a major 
component of the infiltrate of most, if not all, tumours [15]. TAM derive from circulating monocytic 
precursors, and are directed into the tumour by chemoattractant cytokines called chemokines. Many 
tumour cells also produce cytokines called colony-stimulating factors that prolong survival of TAM. 
Furthermore, TAM also produce growth and angiogenic factors as well as protease enzymes which 
degrade the extracellular matrix. Hence, TAM can stimulate tumour-cell proliferation, promote 
angiogenesis, and favor invasion and metastasis [16,17]. Cytokines, including interleukins (IL), TNF-α, 
growth factors and colony-stimulating factors, are secreted or membrane-bound molecules that play a 
regulatory role in the growth, differentiation, and activation of immune cells [18]. Cytokine signaling 
could contribute to the progression of tumours in two aspects: the stimulation of cell growth and 
differentiation and the inhibition of apoptosis of altered cells at the inflammatory site [18]. 
Chemokines include the largest family of cytokines. Most tumours produce chemokines of the two 
major groups, α (or CCX) and β (or CC) [19,20]. In the inflammation process, chemokines, usually 
induced by cytokines, are major soluble regulators that control the directional migration of leukocytes 
to the inflammatory site. It is well established that chemokines are involved in the promotion of 
cancer. Moreover, chemokines also facilitate tumour invasion and metastasis in various cancer types 
and the balance between chemokines with proangiogenic and angiostatic activities is critical in 
regulating angiogenesis. Mechanistically, chemokines may contribute to tumour invasion and 
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metastasis by mediating the directional migration of tumour cells to specific distal organs via 
circulation in a similar manner to its control of leukocyte migration [21–24]. 
Therefore, the relationship between cancer and inflammation is not simple but rather it is a 
complicated pathologic processes under the control of many driving forces. To address the details of 
development of inflammation- associated cancers, and further the transition from inflammation to 
cancer, it is necessary to investigate the specific roles of key regulatory molecules involved in this 
process. Here we centre the attention on cyclooxygenase (COX), which plays a key role in cell 
homeostasis, angiogenesis and tumourigenesis. The function of COX in linking inflammation to 
cancer is now becoming the target of intense investigation and starting to have implications for cancer 
prevention and treatment. 
2. Cyclooxygenase-2 
Cyclooxygenase is a rate-limiting enzyme in the synthesis of prostaglandins (PGs). It catalyses the 
conversion of arachidonic acid to PGG2, then to PGH2 which is subsequently converted to various 
physiologically active prostanoids, including PGE2, PGD2, PGF2a, PGI2 (prostacyclin) and 
thromboxane A2 (TXA2) by the relevant enzymes in a variety of cell types [25,26]. The COX enzyme 
exists in three isoforms, commonly referred to as COX-1, COX-2, and COX-3 [27,28]. COX-1 is 
expressed constitutively in many tissues and mediate the "housekeeping" functions such as 
cytoprotection of gastric mucosa, regulation of renal blood flow and platelet aggregation. In contrast, 
COX-2 is not detected in most normal tissues, but its expression may be induced mainly at sites of 
inflammation in response to inflammatory stimuli including pro-inflammatory cytokines such as IL-1α/β, 
interferon-γ (IFN-γ), TNF-α and growth factors [27]. COX-3, a novel COX-1 splice variant (now 
called COX-1b) has been identified in canine tissue (most abundant in cerebral cortex) as an 
acetaminophen-sensitive isoform. However, the implication of this splice variant in humans is still not 
known [28]. 
The stimulation of COX-2 expression in Src-transformed fibroblasts, endothelial cells and 
monocytes treated with the tumour promoter tetradecanoylphorbol acetate or lipopolysaccharide led to 
the notion that COX-2 is an inducible enzyme that produces prostaglandins during inflammatory and 
tumourigenic settings [29]. A review article on this issue showed that COX-2 is up-regulated from 
51% up to 100% of the tumours by Northern blot, reverse transcription polymerase chain reaction, 
immunoblotting and immunohistochemistry [30]. 
The up-regulation of COX-2 results in an increased synthesis of PGs. Prostaglandins exert their 
effects locally in both autocrine and paracrine patterns. In particular PGE-related to COX-2  
up-regulation appeared strongly involved in the carcinogenetic process. PGE2 effects are mediated by 
a family of G-protein-coupled receptors, namely, EP1, EP2, EP3, and EP4 [31]. In some cell types, 
nuclear peroxisome proliferator-activated receptors (PPAR) are also involved in mediating the PG 
effects [32]. In a recent study in CRC cells, PGE2 promoted cell growth and motility via the EP4 
receptor by activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt/PKB) 
pathway. Interestingly, EP2 and EP3 were also expressed in the CRC cells and their binding affinities 
to PGE2 are similar to EP4 [33]. 
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The only other COX-2 derived PG implicated in oncogenesis is TxA2, which was reported to 
promote tumour growth and angiogenesis [34]. Moreover, it has been reported that TxA2 synthase 
inhibitor blocks colorectal carcinoma liver metastasis in an in vitro study [35]. COX-2 is involved in 
the carcinogenesis process throughout cellular proliferation, antiapoptotic activity, angiogenesis, and 
immune response. 
2.1. Proliferation and apoptosis 
Prostaglandins stimulate proliferation of different cell lines derived from gastrointestinal tract such 
as colonic, intestinal, gastric and esophageal cell lines. COX-2 derived PGE2 promotes human cancer 
cell growth by autoregulation of COX-2 expression, which depends primarily on PGE2 induced 
activation of the Ras-MAPK pathway [36]. 
Overall data from literature show that COX-2 inhibits apoptosis through three different pathways: 
the Bcl-2 mediated pathway, the nitric oxide pathway, and that of ceramide [37]. The role of COX-2 in 
preventing apoptosis is likely mediated by COX-2 derived PGE2, which attenuates cell death induced 
by the COX-2 selective inhibitor SC-58125 [38]. PGE2 induces antiapoptotic protein expression such 
as Bcl-2 and increases nuclear factor kappa B (NF-κB) transcriptional activity, which is a key 
antiapoptotic mediator [39]. 
COX-2-derived PGs regulate programmed cell death and reduce the apoptotic rate via inhibition of 
the mitochondrial apoptotic pathway characterized by reduced cytochrome C release, attenuated 
activation of caspase-9 and -3 and up-regulation of bcl-2 [36]. Additionally, increased prostanoid 
generation due to COX-2 overexpression specifically inhibits Fas-mediated apoptosis [40]. These 
findings have stimulated great interest in identifying COX-2 as a target for modulating apoptosis. 
In vivo, both non-selective and selective COX-2 inhibitors stimulate apoptosis in APC-deficient 
cells that have not yet undergone malignant transformation. This is also seen clinically in familial 
adenomatous plyposis (FAP) patients treated with sulindac and in experimental studies of ApcMin 
mice and rats exposed to chemical carcinogens [41–45]. Non-selective COX-2 inhibitors lose their 
ability to inhibit chemically induced tumours when polyps undergo malignant transformation. In 
contrast, selective COX-2 inhibitors stimulate apoptosis and suppress growth in many carcinomas, 
including cultured human cancers of the stomach [46], esophagus [47], colon [48], and pancreas [49]. 
2.2. Angiogenesis 
The formation of new blood vessels by angiogenesis to provide adequate blood supply is a key 
requirement for the growth of many tumours. While normal blood vessels express the COX-1 enzyme, 
new angiogenic endothelial cells express the inducible COX-2. Overexpression of COX-2 in CRC 
cells induces the production of angiogenic factors such as vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), IL-8, TNFα, platelet derived growth factor (PDGF) and PGs. 
Several reports demonstrated that PGE2 up-regulates VEGF in cultured human fibroblasts and increases 
VEGF and bFGF expression through stimulation of ERK2/JNK1 signaling pathways in endothelial cells 
[50–52]. Interestingly, VEGF and bFGF induce COX-2 and subsequent PGs production in endothelial 
cells, suggesting that the effects of PGE2 on regulation of VEGF and bFGF are likely amplified 
through a positive feedback loop [53]. More recently, PGE2 has been shown to regulate angiogenesis 
Pharmaceuticals 2010, 3                  
          
2499
through the modulation of a chemokine receptor signalling by modulating bFGF-induced chemokine 
receptor-4, that is important for microvessel assembly in vivo, and inducing the pro-angiogenic 
chemokine CXCL-1 in vivo [54]. PGE2 may also stimulate the transcription of the hypoxia inducible 
factor-1 (HIF-1) and work concomitantly with the hypoxic tumour microenvironment to orchestrate 
the process of angiogenesis [55]. 
The contribution of COX-2 at multiple points in the angiogenetic cascade makes it an ideal target in 
the pharmacological inhibition. Both non-selective and selective COX-2 inhibitors inhibit angiogenesis 
through a combined inhibition of angiogenic growth factors production, response to angiogenic factor 
and impairment of endothelial cell survival and migration. Inhibition of COX-2 activity in endothelial 
cells by COX-2 inhibitors resulted in a diminished integrine V3-dependent activation Cdc42 and 
Rac, two members of the Rho family of GTPases that regulate cytoskeletal organization and cell 
migration, resulting in FGF-2-induced angiogenesis in vivo [56]. 
2.3. Immune response 
The tumour microenvironment is predominantly shifted from a Th1 to a Th2 dominant immune 
response [57]. PGE2 has been shown to down-regulate Th1 cytokines (TNF-α, IFN-γ and IL-2) and 
up-regulate Th2 cytokines such as IL-4, IL-6 and IL-10 [58,59]. Moreover, PGE2 can modulate 
immune function through inhibiting dendritic cell differentiation and T cell proliferation and 
suppressing the antitumour activity of natural killer cells and macrophages [58]. In addition, PGE2  
up-regulates the complement regulatory protein decay accelerating factor which results in blocking the 
complement C3 into two active compounds, C3a and C3b in CRC cells [60]. This ability of PGE2 to 
suppress these immune responses may allow tumour cells to escape immunosurveillance, adding to the 
already countless roles of the COX-2/PGE2 pathway during tumour development. COX-2 selective 
inhibitors restore the tumour induced imbalance between Th1 and Th2 and promote antineoplastic 
responses in lung cancer and metastatic spread of CRC [61,62]. These findings led to extensive efforts 
to understand how PGE2 can regulate immunosuppression. 
2.4. COX inhibitors and cancer chemoprevention 
Non-steroidal anti-inflammatory drugs (NSAIDs) block both COX-1 and COX-2 isoenzymes. In 
addition to the beneficial effects on the treatment of pain and inflammation, the use of NSAIDs is 
linked to other beneficial effects in the prevention and treatment of gastrointestinal tract tumours. The 
National Cancer Institute has tested many NSAIDs, such as ibuprofen, indomethacin, ketoprofen, 
piroxicam, and sulindac for chemopreventive activity [63]. However, the prolonged use of these 
compounds is limited by gastric (bleeding and ulcers) and kidney toxicity [64–67]. In addition, the use 
of steroidal antiinflammatories or glucocorticoids (e.g. dexamethasone) which can also inhibit  
COX-2 [68,69], is limited in the chemoprevention setting because of long-term adverse effects 
(adrenal cortical suppression). Recently, selective COX-2 inhibitors (valdecoxib, rofecoxib, celecoxib, 
and others yet in development) has been developed to minimize gastrointestinal toxicity because of the 
relative paucity of COX-2 expression in the gastrointestinal tract and the relative abundance of COX-2 
expression in inflamed and painful tissues. However, selective inhibition of COX-2 might increase the 
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risk for thrombotic cardiovascular events, due to a relative reduction in endothelial production of 
prostacyclin, while leaving the platelet production of TXA2 intact [70,71]. 
More long-term data are needed to fully evaluate the extent to which these important adverse side 
effects may be offset by other beneficial effects of NSAIDs and selective COX-2 inhibitors in cancer 
chemoprevention.  
2.5. Esophageal carcinogenesis 
Esophageal adenocarcinoma (EAC) is generally considered to develop from gastroesophageal 
reflux disease through Barrett’s esophagus (BE). Over the past years, accumulating evidence has been 
obtained suggesting that increased COX-2 expression could be responsible for chronic inflammation 
related esophageal cancer promotion. Indeed, the incidence of COX-2 protein expression gradually 
increases with the development of esophageal lesions, from 75% in metaplasia, to 83% in low-grade 
dysplasia and up to 100% in high-grade dysplasia and EAC [72]. Shirvani et al. demonstrated that the 
expression of COX-2 increases parallel to the grade of dysplasia observed in BE [73]. Moreover, the 
same group demonstrated in an ex vivo model that both gastric acid and bile significantly elevated the 
expression of COX-2 [73]. Zhang et al. using a duodenogastroesophageal reflux model including 
unconjugated and conjugated bile acids, reported increased COX-2 expression in the esophageal 
mucosa followed by PGE2 production. Further, increased PG synthesis caused stimulation of cell 
proliferation and contributed to the development of dysplasia in Barrett's epithelium [74]. A recent 
metanalysis by Abnet et al. found a significant reduction in the incidence of esophageal cancer in 
aspirin or non-aspirin NSAID users (OR 0.64; 95% CI, 0.52–0.79 and OR 0.65; 95% CI,  
0.50–0.85 respectively) [75]. 
Experimental models have demonstrated reduced expression of an apoptosis ligand, Fas (CD-95), in 
esophageal dysplastic and malignant tissues [76]. This reduced expression is linked to overexpression of 
COX-2, which in turn down-regulates the expression of Fas ligand [40]. A mechanism for the inhibitory 
effects of aspirin and NSAIDs on the occurrence of EAC could be the induction of apoptosis by COX-
2 inhibition. Overexpression of COX-2 also was associated with increased levels of bcl-2, a 
proapoptotic protein that induced resistance to apoptosis [77]. Therefore, selective COX-2 inhibitors 
may up-regulate the expression of Fas receptors on the cell surface in subjects with Barrett dysplasia 
and have an inhibiting role in esophageal carcinogenesis by influencing apoptosis and cellular 
proliferation. Finally, COX-2 expression might be a prognostic marker in patients with Barrett's 
adenocarcinoma, as expression of COX-2 correlates with patient survival. Further support for the role 
of COX-2 derived PGs in the carcinogenesis emerged from the animal study by Buttar et al. in which 
both non-selective COX inhibitor (sulindac) and selective COX-2 blocker (MF tricyclic) significantly 
attenuated the incidence of Barrett adenocarcinoma [78]. Moreover, Kaur et al. studied the effect of 
COX-2 inhibitor (rofecoxib) on the marker of cell proliferation PCNA. In BE the authors found a 
significant increased PCNA expression as compared to normal esophageal mucosa. In addition, 
therapy with rofecoxib caused a significant inhibition of cell proliferation as evidenced by the 
decreased PCNA expression. Rofecoxib therapy led also to significant down-regulation of COX-2 
expression in the Barrett's epithelium [79]. The suppressive effects of a COX-2 inhibitor, NS398, on 
the epithelium of BE have been demonstrated in two independent in vitro studies [80,81]. An increase 
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in apoptosis and a suppression of cell proliferation are supposed to be responsible for the inhibition of 
cancer cells. Furthermore, in a study carried out using a carcinogen-induced rodent model, selective 
COX-2 inhibitors have been reported to prevent the development of esophageal cancer. N-
nitrosomethylbenzylamine-induced esophageal tumourigenesis in rats was prevented by the 
administration of another selective COX-2 inhibitor, JTE-522 [82]. Nevertheless, a Chemoprevention 
Barrett's Esophagus Trial (CBET) started in 2003 as a phase IIb, multicenter, randomized, double-
masked, placebo-controlled study of celecoxib in patients with Barrett's dysplasia failed to prevent 
progression of Barrett’s dysplasia to cancer. However, the apparent inability of celecoxib, compared 
with placebo, to decrease the percentage of samples with dysplasia is probably due to the several 
limitations of the study (previous diagnosis of displasia but no evidence of displasia at enrollment, 
imperfect biopsy sampling, natural reversion of dysplasia without any intervention, inadequate 
utilization of dysplasia grading as predictor of cancer because of the low intra- and interobserver 
agreement among pathologists) [83]. 
2.6. Gastric carcinogenesis  
Gastric cancer (GC) is one of the most frequent malignancies worldwide [84]. The development of 
GC, at least of intestinal type, occurs on the basis of atrophy-metaplasia-dysplasia-sequence [85]. This 
multistep process is triggered by Helicobacter pylori (H. pylori) infection [85]. Indeed, the colonization 
of gastric mucosa with this bacterium causes a chronic inflammatory reaction with increased production 
of proinflammatory cytokines and generation of reactive oxygen species [86]. Interestingly, the presence 
of H. pylori also correlates with an up-regulation of the expression of COX-2 mRNA and PGE2 in GC 
cell lines [87]. 
Normal gastric mucosa scarcely expresses COX-2, but the expression of COX-2 and the 
production of eicosanoids (especially PGE2) increases through the multistep process of gastric  
carcinogenesis [88,89]. Ristimaki et al. described for the first time in 1997 an elevated expression of 
COX-2 in GC [90]. Since then, numerous studies have reported the relationship between COX-2 
expression and gastric carcinogenesis. Sun et al. by immunohistochemistry reported a progressive 
positive rate of COX-2 from superficial gastritis, to gastric atrophy, intestinal metaplasia, dysplasia, and 
cancer (10.0%, 35.7%, 37.8%, 41.7%, and 69.5%, respectively) [91]. The COX-2 expression is more 
frequent in intestinal type than in diffuse type GC [92,93], and it also correlates with tumour size, depth 
of invasion, lymph node metastasis, lymphatic invasion, clinical stage, and prognosis [94–98]. This 
suggests that COX-2 expression may be an early event in gastric carcinogenesis process even if, the 
precise mechanisms leading to the overexpression of COX-2 are still not fully understood. However, 
there is evidence that proinflammatory cytokines and different gastric mucosal growth factors such as 
transforming growth factor alpa (TGFα) or hepatocyte growth factor (HGF) or finally gastrin could be 
involved in this process [99]. 
Previous studies demonstrated an increased gastrin level in the GC tissue. Gastrin is a potent 
stimulator of HGF expression and possesses also anti-apoptotic capabilities by inducing the 
antiapoptotic- proteins Bcl-2 and surviving [100,101]. The importance of gastrin and its precursor 
progastrin in mediating of COX-2 dependent gastric carcinogenesis was demonstrated in humans with 
GC treated with COX-2 inhibitor rofecoxib [102]. Treatment of GC patients with rofecoxib (50 mg/day) 
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resulted in a significant decrease in plasma and tumour contents of both progastrin and gastrin levels, 
and this was accompanied by the increased expression of proapoptptic proteins such as Bax and 
caspase-3 with a concomitant reduction in Bcl-2 and survivin expression. The blockade of COX-2 was 
also associated with a decrease in the serum level of proinflammatory cytokines IL-8 and TNF being 
also involved in the gastric carcinogenesis [103]. 
Experimental evidence has shown that COX-2 influences key cellular events, including apoptosis, cell 
cycle control, cell proliferation, and angiogenesis [50,77,104–106]. Selective COX-2 inhibitors (NS-398 
and JTE-522), indomethacin, and aspirin can suppress cell replication, induce apoptosis, and reduce 
epidermal growth factor in gastric carcinoma cell lines (KATO III) [107–109]. Nam et al. examined the 
effect of nimesulide on gastric carcinogenesis using an N-methyl-N-nitrosourea (NMU)-induced and an  
H pylori-infected mouse model, demonstrating that gastric tumours developed in 68.8% of mice given 
both MNU and H pylori, whereas the tumour incidence in the mice receiving nimesulide in addition to 
MNU and H pylori was 27.8% [110]. More recently COX-2 was proven to have a strong relationship 
with gastric tumourigenesis in a study using transgenic mice. In the transgenic model expressing both 
COX-2 and microsomal prostaglandin E synthase (mPGES)-1, the animals developed inflammation- 
associated hyperplastic gastric tumours in the proximal glandular stomach [111]. In addition, NS-398 
treatment for four weeks completely suppressed the gastric hypertrophy, thereby reducing the mucosal 
thickness in the same model [112]. 
Epidemiologic studies also have shown a decreased frequency of GC in people who take NSAIDs, 
Several case-control and cohort studies on NSAIDs use in gastric carcinoma have demonstrated a 
chemopreventive effect of NSAIDs [113–115]. Coogan et al. found that regular NSAID use (at least  
4 days a week for >3 months) reduced the risk of GC in a hospital-based-case-control study of  
254 patients (OR 0.3; 95% CI, 0.1–0.6). The protective effect was more pronounced among those 
patients using NSAIDs continually for >5 years (OR 0.2; 95% CI, 0.1–0.7) than for those using 
NSAIDs for <5 years (OR 0.4; 95% CI, 0.1–0.9) [114]. In a large cohort study of 635,031 subjects 
followed over 6 years, the American Cancer Society demonstrated that regular exposure to aspirin  
(>16 times/month) exerted a protective effect against GC; aspirin users were found to have 
approximately 50% the risk of GC compared with nonusers (OR = 0.53; 95% CI, 0.34–0.81) [93].  
A recent metanalysis by Abnet et al. found a significant reduction in the incidence of GC in aspirin or 
non-aspirin NSAID users (OR 0.74; 95% CI, 0.64–0.87 and OR 0.79; 95% CI, 0.71–0.89  
respectively) [75]. 
This evidence suggests that inhibition of COX-2 may be an attractive target for treatment and 
prevention of GC. However, upper gastro intestinal bleeding is a common side-effect of aspirin 
therapy, so co-administration of aspirin and proton-pump inhibitors is an attractive option in this 
setting, and is currently being studied in the AspECT study of esomeprazole and aspirin in patients 
with Barrett’s esophagus [116]. 
2.7. Colorectal carcinogenesis 
Colorectal cancer is one of the most popular cancers in westernized countries [117]. CRC develops 
in a stepwise manner from aberrant crypts to adenomas, with increasing grade of dysplasia and finally 
to cancer. According to this adenoma-carcinoma sequence model, carcinogenesis proceeds through the 
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accumulation of series of epigenetic and genetic alterations involving several tumour-suppressor genes 
(i.e., APC and p53) and oncogenes (i.e., k-ras) [118,119]. Among these COX-2 oncogene has been 
most intensively elucidated in both basic and clinical research due to its pathogenetic implication. 
In normal human epithelium, COX-2 generally is down-regulated and is not expressed in the 
gastrointestinal tract. Dubois et al. were the first to report increased expression of COX-2 in CRC [120]. 
Their original observation was followed by several reports that confirmed increased COX-2 expression 
in this setting. An epoch-making paper was published by Oshima et al. in 1996 about the contribution 
of COX-2 to carcinogenic sequence in Wnt/Apc/Tcf pathway. They induced COX-2 mutations in 
ApcΔ716 knockout mice, which led to the development of numerous polyps in the intestine. In  
COX-2−/− ApcΔ716 and COX-2+/− ApcΔ716 mice, the number of polyps dramatically decreased by 
86% and 66%, in comparison to that in the littermate COX-2+/+ ApcΔ716 mice [121].  
Many studies have demonstrated that COX-2 is expressed early during the adenoma-carcinoma 
sequence, suggesting COX-2 should be in first line linked to the colorectal carcinogenesis. COX-2 
expression is up-regulated by approximately 50% in colorectal adenoma [122] and 85–90% in  
CRC [105]. COX-2 overexpression appears to be associated with both the histological type and the 
location of the tumours. Overexpression was less prominent in tumours with signet cell morphology 
and was found more frequently in rectal carcinoma compared to carcinoma at others sites in the  
colon [123,124]. Furthermore the overexpression of COX-2 in CRCs appears to be associated with the 
genetic and epigenetic make-up of the tumours being significantly lower in proximal carcinomas that 
has the micro satellite instability (MSI) phenotype [123]. 
COX-2 is also expressed in the stromal compartment of adenomatous polyps and of invasive 
carcinomas both in experimental animal models and in humans. These stromal cells have the 
morphological and immunohistochemical characteristics of inflammatory cells [125–127]. 
Transfection of human CRC cells with a COX-2 expression vector resulted in increased 
invasiveness and activation of matrix metalloproteinases compared to the parental cell line. COX-2 
overexpressing cells also produced proangiogenic factors, stimulated endothelial migration and tube 
formation and produced the proangiogenic factor VEGF [128]. 
In chemically (1,2-dimethyldralazine -DMH- and azoxymethane -AOM-), induced CRC in rat, the 
inhibition of PGs by non-selective NSAIDs and selective COX-2 inhibitors significantly reduced 
formation of aberrant crypts and development of adenomas and CRC [129]. Moreover, coxibs 
(rofecoxib) and non-selective NSAID (sulindac) significantly reduced the number and size of intestinal 
polyps in the mice with dysfunctional APC gene (APCD716 mice) [130]. Jacoby et al. by using the 
Min mice model showed that celecoxib decreased not only tumour size but also caused a decrease in 
the size of established polyps in the regression study [131]. 
In human CRC cell lines, HCA-7, which express high levels of COX-2 protein constitutively, and 
HCT-116 cells, which lack COX-2 protein, studies were conducted to investigate the relationship 
between inhibition of intestinal cancer growth and selective inhibition of the COX-2 pathway. 
Treatment of nude mice implanted with HCA-7 cells with a selective COX-2 inhibitor (SC-58125) 
reduced tumour formation by 85–90%. Colony formation of cultured HCA-7 cells also was inhibited 
by SC-58125. On the other hand, SC-58125 had no effect on HCT-116 implants in nude mice or 
colony formation in culture [132]. In addition Chan et al. found that regular use of aspirin appears to 
reduce the risk of CRCs that overexpress COX-2 (RR 0.64; 95% CI, 0.52–0.78) but not the risk of 
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CRCs with weak or absent expression of COX-2 (RR 0.94; 95% CI, 0.73–1.26) [133]. This evidence 
suggests that a correlation may exist between inhibition of CRC cell growth and selective inhibition of 
the COX-2 enzyme. 
In a National Cancer Institute-sponsored double-blind, placebo-controlled trial, celecoxib helped to 
reduce the number of colon polyps that occurred in patients with FAP. In this study, 77 patients were 
randomly assigned to treatment with celecoxib (100 or 400 mg twice/day) or placebo for 6 months. 
After 6 months, the patients receiving celecoxib 400 mg twice/day had a 28.0% reduction in the mean 
number of colorectal polyps (p = 0.003) and a 30.7% reduction in the polyp size (p = 0.001), as 
compared with reductions of 4.5% and 4.9%, respectively, in the placebo group. The occurrence of 
adverse events was similar among the groups [134]. The results of the study led to the approval of 
celecoxib by the United States Food and Drug Administration (FDA) as an adjunct to usual care for 
patients with FAP. In, another placebo-controlled study, rofecoxib given daily at a dose 25 mg, 
significant decreased the size and number of rectal polyposis in patients with FAP after 9 months 
[135]. Finally, Phillips et al. showed a significant reduction in duodenal polyps in patients with FAP 
treated with selective COX-2 inhibitor [136]. 
The data obtained from FAP patients encouraged the conduction of further studies in patients with 
sporadic adenomas and CRC. Baron et al. investigated the adenoma recurrence in 1121 patients with a 
history of sporadic colorectal adenomas randomized to receive placebo (n = 372), 81 mg aspirin (n = 377) 
or 325 mg of aspirin (n = 375) daily. Relative risks for advanced lesions were 0.59 (0.38–0.92) in the 
81 mg group and 0.83 (0.55–1.23) in 325 mg group as compared to placebo. Surprisingly, the lower 
aspirin dose had stronger chemopreventive effect that the higher one. However, the assessment of 
possible chemopreventive effect of aspirin on colorectal carcinogenesis was limited by the short 
follow-up time of the study [137]. A recent prospective cohort study involving 1,279 subjects (549 
who regularly used aspirin, 730 who did not use aspirin) with a diagnosed CRC, followed up to 12 
years has shown a lower risk of CRC specific and overall mortality in aspirin users vs non-users (HR 
0.71; 95% CI, 0.53-0.95). [138]. The Approve trial, a randomized multicenter, placebo controlled, 
double blind trial to investigate whether the chronic use of the coxib (rofecoxib 25 mg daily) would 
reduce the adenoma recurrence in 2,586 patients with a history of colorectal adenomas. Therapy with 
rofecoxib was associated with a significant reduction in adenoma number and size. Unfortunately, an 
increase in rofecoxib associated cardiovascular adverse events beginning at 18 months was also noted, 
which led to early study termination [139]. Similarly, Bertagnolli et al. in a five-years efficacy and 
safety analysis of the adenoma prevention with celecoxib trial, found an inhibitory effect of celecoxib 
in colorectal adenoma formation but they reported an elevated risk for cardiovascular and thrombotic 
adverse events [6% (RR, 1.6; 95% CI, 1.0–2.5) and 7.5% (RR, 1.9; 95% CI, 1.2–3.1) in celecoxib 200 
and 400 mg twice daily users, respectively compared to 3.8% in placebo group [140]. 
The role of COX-2 inhibitors has been investigated in the treatment of advanced human CRC. The 
14-day therapy with celecoxib (200 mg/day) caused a significant decrease in the progastrin and gastrin 
levels in the CRC tissue as well as significant decrease in the survivin expression [141]. Based upon 
these results it has been hypothesized that celecoxib therapy could contribute to the treatment of CRC 
via suppression of the anti-apoptotic proteins and reduction in progastrin-promoted tumour growth. 
Since the overexpression of COX-2 in tumour may counteract the efficacy of cytotoxic chemotherapy 
due to the apoptosis resistance, the combination of chemotherapy with coxibs seems to be an attractive 
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strategy to enhance the antitumour activity. Until now, the number of clinical studies in which rofecoxib 
was administered with chemotherapy in patients with CRC is very limited. Beccera et al. reported a 
phase II study in which rofecoxib was administered in combination with 5-fluorouracil and leucovorin 
in patients with metastatic CRC. The study was terminated when it was noted an increased toxicity 
(upper gastrointestinal bleeding, stomatitis, thrombocytopenia, diarrhea) in patients treated with 
chemotherapy and rofecoxib [142]. The addition of COX-2 inhibitor to the chemotherapy did not 
increase the efficacy of the antitumour activity of the chemotherapy. Despite these disappointing 
results, further studies with chemotherapy and COX-2 inhibitors will be needed to determine whether 
specific COX-2 therapy is able to improve patient outcome with a reasonable safety profile. 
Finally, there are some groups postulating that both COX-isoforms are involved in the intestinal 
tumourigenesis. Chulada et al. demonstrated that deficiency of either COX-1 and COX-2 caused 
similar reduction in intestinal tumourigenesis in Min mice having a mutation in the APC gene and 
spontaneously developing intestinal adenomas . Furthermore, both COX-isoforms contributed to PGE2 
production in polyps [143]. Finally, the inhibitory effect of non-selective NSAIDs and coxibs was 
demonstrated in xenograft mice models in which CRC cell lines are injected and form tumours with 
metastasis [62].  
3. Conclusions 
Mounting evidence gained from studies with cancer cell lines, mouse models and a number of 
clinical trials with both non-selective and selective COX-2 inhibitors support the notion of an 
important role for the COX-PG pathway in the development of gastrointestinal tumours. However, the 
mechanisms of the anti-tumoural action of the COX-2 inhibitors still remain to be defined and may 
vary from agent to agent and tumour to tumour. 
In vitro studies have shown a mixture of COX-related mechanisms in controlling proliferation and 
apoptosis balance. Animal model studies are often performed with much higher pharmacological doses 
than those clinically achievable. Human observational studies are prevalently of the case-control type 
and often suffer from inadequate sample size to avoid a type II statistical error. In addition, more 
studies are needed to define the lowest effective dose, the age at which to initiate therapy, the optimum 
treatment duration and the subpopulations for which the benefits of chemoprevention outweigh the 
risks of adverse side effects. Furthermore, due to the high cost of these new agents, cost-effectiveness 
analyses must be carried out to optimize the allocation of resources. The cumulative probability of 
developing a lesion from birth to 80 years of age is less than 4% thus, in the general population, more 
than 95% of people treated prophylactically with COX-2 inhibitors will not benefit. 
Understanding the molecular mechanisms of COX-2 and its downstream targets will help to 
identify specific molecular targets for developing new drugs which target this pathway, however, until 
now inconsistency still exists regarding the specific role of COX-2 in linking inflammation and cancer.  
4. Future Directions 
There are many reasons to be optimistic that tumour formation mediated by abnormal COX-2 
activity can be effectively and safely targeted by chemoprevention regimens. Available anti-COX-2 
agents vary substantially in their activities, with different degrees of COX-1 versus COX-2 selectivity, 
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differences in antitumour efficacy, and differences in toxic effects. In the balance of factors that 
maintain control over the highly reactive prostaglandin system, small differences in agent selectivity, 
dose, drug metabolism, and patient reactivity or predisposition to toxic effects could be important. 
Presently, we have little information about the relation between these important variables and agent 
efficacy and toxic effects. The rapid development of safe and effective inhibitors targeting individual 
COX enzymes could not only dramatically improve our understanding of the function of COX-2, but 
also result in discovery of COX independent functions of NSAIDs, providing important hints for 
future drug design.  
An exciting, novel concept in cancer chemoprevention may be the use of combination therapy, 
which may allow dose reduction (and hence decreased systemic bioavailability) of NSAIDs or coxibs 
when combined with other anti-cancer agents, e.g., epidermal growth factor receptor inhibitors. 
Alternatively, other steps in PG biosynthesis and signalling represent potential targets. Indeed, 
pharmacological inhibitors of PGE2-EP receptors, which have anti-neoplastic activity, have been 
generated. Development of specific inhibitors for individual enzymes and receptors will be dependent 
on better understanding of the roles of particular PGs and their signaling receptors in health and 
disease. Finally, inducible expression of COX-2 is tightly controlled at the transcriptional and 
translational level in a cell-specific manner. Therefore, targeting mechanisms controlling neoplastic 
COX-2 regulation in stromal and epithelial elements of tumours may provide an alternative in tumour-
specific COX-2 inhibition, avoiding the side effects related to systemic COX-2 inhibition. 
In the light of an innovative alternative to these pharmacological approaches, it has been proposed 
the possible strategy to achieve a strong and selective inhibition of COX-2 enzyme by using the 
mechanism of RNA Interference targeted against its mRNA. Anti-COX-2 RNA molecules can be 
generated in CRC cells from short hairpin RNA precursors, delivered in vitro by a retroviral 
expression system, and induce a significant and stable silencing of overexpressed COX-2 in human 
CRC cells. As a safer alternative to viral approach, nonpathogenic bacteria (E. coli) can be engineered 
to invade eukaryotic cells. Moreover, the involvement of micro-RNAs in COX-2 posttranscriptional 
regulation opens up the possibility to exploit an endogenous silencing mechanism to knockdown 
overexpressed COX-2. Thus, these recent strategies disclose new challenging perspectives for 
selectively inhibiting COX-2 enzyme. 
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